TABLE OF CONTENTS
Volume 12, Issue 1 (March 2009)
Editorial
Report from Durham FREE
J Moul Co-Editor
Prostate Cancer Prostatic Dis 12: 1; doi:10.1038/pcan.2009.1
Research Highlights
Prostate News FREE
Prostate Cancer Prostatic Dis 12: 2-5; doi:10.1038/pcan.2008.59
Reviews
HIV and prostate cancer: a systematic review of the literature FREE
J Silberstein, T Downs, C Lakin and C J Kane
Prostate Cancer Prostatic Dis 12: 6-12; advance online publication, August 19, 2008; doi:10.1038/pcan.2008.44
Prostate cancer chemotherapy in the era of targeted therapy FREE
A Michael, K Syrigos and H Pandha
Prostate Cancer Prostatic Dis 12: 13-16; advance online publication, June 3, 2008; doi:10.1038/pcan.2008.32
Original Articles
Prostatic fluid electrolyte composition for the screening of prostate cancer: a potential solution to a major problem FREE
L C Costello and R B Franklin
Prostate Cancer Prostatic Dis 12: 17-24; advance online publication, July 1, 2008; doi:10.1038/pcan.2008.19
Differential mechanisms of bicalutamide-induced apoptosis in prostate cell lines FREE
M St John Floyd Jr, S J Teahan, J M Fitzpatrick and R W G Watson
Prostate Cancer Prostatic Dis 12: 25-33; advance online publication, May 13, 2008; doi:10.1038/pcan.2008.23
Molecular targeting of Bcl-2 overcomes prostate cancer cell adaptation to XIAP gene downregulation FREE
Y Nakano, V Bilim, K Yuuki, A Muto, T Kato, A Nagaoka and Y Tomita
Prostate Cancer Prostatic Dis 12: 34-40; advance online publication, May 13, 2008; doi:10.1038/pcan.2008.27
Pericyte coverage decreases invasion of tumour cells into blood vessels in prostate cancer xenografts FREE
K Welén, K Jennbacken, T Te
an and J-E Damber
Prostate Cancer Prostatic Dis 12: 41-46; advance online publication, June 3, 2008; doi:10.1038/pcan.2008.33
Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA? FREE
D Connolly, A Black, L J Murray, T Nambirajan, P F Keane and A Gavin
Prostate Cancer Prostatic Dis 12: 47-51; advance online publication, September 2, 2008; doi:10.1038/pcan.2008.37
Incidence of prostate cancer in male breast cancer patients: a risk factor for prostate cancer screening FREE
U J Lee and J S Jones
Prostate Cancer Prostatic Dis 12: 52-56; advance online publication, May 27, 2008; doi:10.1038/pcan.2008.26
Probability of finding T1a and T1b (Incidental) prostate cancer during TURP has decreased in the PSA era FREE
J S Jones, H W Follis and J R Johnson
Prostate Cancer Prostatic Dis 12: 57-60; advance online publication, April 1, 2008; doi:10.1038/pcan.2008.14
Biochemical relapse-free survival in 400 patients treated with I-125 prostate brachytherapy: the Guildford experience FREE
J P Nobes, I G Wells, S J Khaksar, J F Money-Kyrle, R W Laing and S E M Langley
Prostate Cancer Prostatic Dis 12: 61-66; advance online publication, April 22, 2008; doi:10.1038/pcan.2008.17
Distress and social dysfunction following prostate cancer treatment: a longitudinal cross-cultural comparison of Japanese and American men FREE
S Namiki, L Kwan, M Kagawa-Singer, A Terai, T Satoh, S Baba, Y Arai and M S Litwin
Prostate Cancer Prostatic Dis 12: 67-71; advance online publication, April 8, 2008; doi:10.1038/pcan.2008.20
Quality of life in patients with prostate cancer: development and application of a hybrid assessment method FREE
P C Stone, R F Murphy, H E Matar and M Q Almerie
Prostate Cancer Prostatic Dis 12: 72-77; advance online publication, May 13, 2008; doi:10.1038/pcan.2008.28
Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients? FREE
T Imamoto, H Suzuki, M Yano, K Kawamura, N Kamiya, K Araki, A Komiya, Y Naya, T Shiraishi and T Ichikawa
Prostate Cancer Prostatic Dis 12: 78-82; advance online publication, June 3, 2008; doi:10.1038/pcan.2008.35
Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe FREE
U W Tunn and K Wiedey
Prostate Cancer Prostatic Dis 12: 83-87; advance online publication, November 25, 2008; doi:10.1038/pcan.2008.52
The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer FREE
A J Armstrong, S Halabi, R de Wit, I F Tannock and M Eisenberger
Prostate Cancer Prostatic Dis 12: 88-93; advance online publication, June 24, 2008; doi:10.1038/pcan.2008.36
Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease FREE
M Tucci, A Mosca, G Lamanna, F Porpiglia, M Terzolo, F Vana, C Cracco, L Russo, G Gorzegno, M Tampellini, M Torta, G Reimondo, M Poggio, R M Scarpa, A Angeli, L Dogliotti and A Berruti
Prostate Cancer Prostatic Dis 12: 94-99; advance online publication, March 11, 2008; doi:10.1038/pcan.2008.10
Case Report
Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists FREE
I M Spitz, B Chertin, A Fridmans, A Farkas, A Belanger, H Hartman and F Labrie
Prostate Cancer Prostatic Dis 12: 100-103; advance online publication, June 24, 2008; doi:10.1038/pcan.2008.15
